14 results on '"Okada, Annabelle A."'
Search Results
2. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study
- Author
-
Tamashiro, Tamaki, Tanaka, Koji, Itagaki, Kanako, Nakayama, Makiko, Maruko, Ichiro, Wakugawa, Sorako, Terao, Nobuhiro, Onoe, Hajime, Wakatsuki, Yu, Ogasawara, Masashi, Sugano, Yukinori, Yamamoto, Akiko, Kataoka, Keiko, Izumi, Takahiko, Kawai, Moeko, Mori, Ryusaburo, Sekiryu, Tetsuju, Okada, Annabelle A., Iida, Tomohiro, and Koizumi, Hideki
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
- Author
-
Okada, Annabelle A., Takahashi, Kanji, Ohji, Masahito, Moon, SungChul Charles, Machewitz, Tobias, and Sasaki, Koji
- Published
- 2022
- Full Text
- View/download PDF
4. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
- Author
-
Kataoka, Keiko, Itagaki, Kanako, Hashiya, Nozumu, Wakugawa, Sorako, Tanaka, Koji, Nakayama, Makiko, Yamamoto, Akiko, Mukai, Ryo, Honjyo, Jyunichiro, Maruko, Ichiro, Kawai, Moeko, Miyara, Yasunori, Terao, Nobuhiro, Wakatsuki, Yu, Onoe, Hajime, Mori, Ryusaburo, Koizumi, Hideki, Sekiryu, Tetsuju, Iida, Tomohiro, and Okada, Annabelle A.
- Subjects
MACULAR degeneration ,AFLIBERCEPT ,POLYPOIDAL choroidal vasculopathy ,CHOROID ,OPTICAL coherence tomography ,DRUG labeling - Abstract
Purpose: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections. Methods: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured by optical coherence tomography. Results: The study included 130 eyes of 124 patients. At 6 months, 53 eyes (40.8%) continued on faricimab treatment (Group 1), while 77 eyes (59.2%) discontinued faricimab for various reasons (Group 2) the most common being worse exudation. There were no significant differences between the two groups at baseline. In Group 1, CRT and SFCT significantly decreased at 1 month (P = 0.013 and 0.008), although statistical significance was lost at 6 months (P = 0.689 and 0.052). BCVA and maximal PED height showed no significant changes; however, mean treatment intervals were extended from 4.4 ± 0.5 weeks at baseline to 8.7 ± 1.7 weeks at 6 months (P < 0.001) in Group 1. No clear predictors of response were identified. Conclusion: Switching from aflibercept to faricimab allowed for extension of treatment intervals from monthly to bimonthly in roughly 40% of eyes, suggesting that faricimab may be considered in refractory nAMD cases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy
- Author
-
Ogasawara, Masashi, Koizumi, Hideki, Yamamoto, Akiko, Itagaki, Kanako, Saito, Masaaki, Maruko, Ichiro, Okada, Annabelle A., Iida, Tomohiro, and Sekiryu, Tetsuju
- Published
- 2018
- Full Text
- View/download PDF
6. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan.
- Author
-
Mukai, Ryo, Kataoka, Keiko, Tanaka, Koji, Miyara, Yasunori, Maruko, Ichiro, Nakayama, Makiko, Watanabe, Yuto, Yamamoto, Akiko, Wakatsuki, Yu, Onoe, Hajime, Wakugawa, Sorako, Terao, Nobuhiro, Hasegawa, Taiji, Hashiya, Nozomu, Kawai, Moeko, Maruko, Ruka, Itagaki, Kanako, Honjo, Jyunichiro, Okada, Annabelle A., and Mori, Ryusaburo
- Subjects
MACULAR degeneration ,POLYPOIDAL choroidal vasculopathy ,CHOROID ,INTRAVITREAL injections ,RHODOPSIN ,VISUAL acuity - Abstract
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy. Over these 3 months, visual acuity improved gradually compared to baseline. Moreover, the central foveal thickness decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). At 3 months after initiation of faricimab therapy, a dry macula (defined as absence of intraretinal or subretinal fluid) was achieved in 82% of the eyes. Complete regression of polypoidal lesions was observed in 52% of eyes with PCV. Subfoveal choroidal thickness also decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). Although retinal pigment epithelium tears developed in two eyes, there were no other ocular or systemic complications observed during the 3 months of loading therapy. In conclusion, loading therapy using faricimab resulted in improved visual acuity and retinal morphology in Japanese patients with wAMD without particular safety issues. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Long-term changes of choroidal blood flow velocity in Vogt-Koyanagi-Harada disease.
- Author
-
Abe, Shinya, Nakamura, Tomoko, Okumura, Erika, Oiwake, Toshihiko, Okada, Annabelle A., and Hayashi, Atsushi
- Subjects
BLOOD flow ,FLOW velocity ,CHOROID ,OPTICAL coherence tomography ,POLYPOIDAL choroidal vasculopathy ,CHOROID diseases - Abstract
Purpose: To evaluate changes in choroidal blood flow in patients with Vogt-Koyanagi-Harada (VKH) disease after initiation of corticosteroid treatment. Methods: Fourteen patients (10 men and 4 women) with acute VKH disease followed for 2 years were retrospectively reviewed; only right eyes were included in the analysis. Mean blur rate (MBR) in the macula was measured by laser speckle flowgraphy (LSFG) and central choroidal thickness (CCT) was measured by optical coherence tomography (OCT), both prior to treatment and over 2 years after initiation of corticosteroid treatment. Results: Of 14 patients included in this study, 13 received initial treatment consisting of intravenous corticosteroid pulse therapy and one patient was treated using bilateral sub-Tenon injections of triamcinolone acetonide. Mean percentage change in MBR was significantly increased after initiation of treatment compared to pretreatment values (P < 0.001). Mean CCTs were significantly decreased after initiation of treatment, compared to pretreatment thicknesses (P < 0.001). There was no significant change in either MBR change or CCT at 1 month after initiation of treatment through 2 years of follow-up. The mean MBR percentage change was significantly higher in eyes with sunset glow fundus (SGF) compared to eyes without SGF at 1 year. Conclusion: With initiation of corticosteroid treatment in VKH disease patients, choroidal blood flow improved and was maintained for 2 years. However, the presence of SGF should be taken into consideration when interpreting MBR results in VKH disease patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Compromised blood flow of the optic nerve head in acute retinal necrosis.
- Author
-
Hayashi, Isami, Keino, Hiroshi, Inoue, Makoto, and Okada, Annabelle A.
- Subjects
OPTICAL flow ,BLOOD flow ,OPTIC nerve ,OPHTHALMIC zoster ,NECROSIS ,POLYPOIDAL choroidal vasculopathy ,DIABETIC retinopathy - Published
- 2022
- Full Text
- View/download PDF
9. Pachychoroid: current concepts on clinical features and pathogenesis.
- Author
-
Castro-Navarro, Veronica, Behar-Cohen, Francine, Chang, Woohyok, Joussen, Antonia M., Lai, Timothy Y. Y., Navarro, Rafael, Pearce, Ian, Yanagi, Yasuo, and Okada, Annabelle A.
- Subjects
RHODOPSIN ,CHOROID ,PHENOTYPES ,PHOTORECEPTORS ,SYMPTOMS ,POLYPOIDAL choroidal vasculopathy - Abstract
Purpose: The term "pachychoroid" refers to a newly described phenotype in which functional and structural choroidal changes are thought to play a key pathogenic role in a spectrum of related retinal disorders. A more detailed understanding of how the choroid is involved within this spectrum and a better knowledge of the most relevant clinical signs of the pachychoroid phenotype are important to differentiate these disorders from other retinal conditions. Our objectives are to provide a literature review of pachychoroid and the commonalities that may be present across pathologies included in the spectrum, and to provide details on the examination, monitoring, and management of these disorders. Methods: We searched the PubMed web platform to identify relevant studies using the following keywords: pachychoroid, pachychoroid pigment epitheliopathy, pachychoroid neovasculopathy, aneurysmal type 1 neovascularization, focal choroidal excavation, peripapillary pachychoroid syndrome, vasculopathy pachysclera, pachychoroid geographic atrophy, and pachydrusen. We selected 157 publications and identified the most important features related to pachychoroid. Results: The presence of hypertrophic or congested vessels in the choroid, not thickened choroid per se, under an area of reduced or absent choriocapillaris in the posterior pole seems to be the most salient feature of pachychoroid. However, other qualitative/quantitative features are needed to differentiate the uncomplicated pachychoroid from the pathological pachychoroid clinical spectrum, which may be associated with exudation, neovascularization, and/or retinal pigment epithelium and photoreceptor atrophy. Conclusions: The most salient feature of pachychoroid appears to be the presence of large vessels under an area of reduced or absent choriocapillaris. Knowledge of the features and pathogenesis of the different disorders in the pachychoroid spectrum may assist in the management of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study.
- Author
-
Koizumi, Hideki, Yamamoto, Akiko, Ogasawara, Masashi, Maruko, Ichiro, Hasegawa, Taiji, Itagaki, Kanako, Sekiryu, Tetsuju, Okada, Annabelle A., and Iida, Tomohiro
- Subjects
POLYPOIDAL choroidal vasculopathy ,RETINAL degeneration ,ATROPHY - Abstract
Purpose: To evaluate the development and rate of growth in macular atrophy after intravitreal injections of aflibercept (IVAs) for neovascular age-related macular degeneration (AMD) over a 2-year period. Study design: Retrospective, interventional, consecutive case series. Methods: This study included 94 eyes of 92 patients with treatment-naïve AMD involving the foveal center treated with IVAs at 3 university hospitals in Japan. The patients underwent IVAs bimonthly after 3 initial monthly doses in the first year. The protocol was converted to a treat-and-extend regimen in the second year. The incidence and growth rate of macular atrophy were quantified based on hypoautofluorescence detected by fundus autofluorescence images. Additionally, possible background factors related to the development and rate of growth of macular atrophy were investigated. Results: Of 94 eyes, 39 (41.5%) had typical AMD and 55 (58.5%) had polypoidal choroidal vasculopathy. Ten eyes (10.6%) had macular atrophy at the baseline. Of the remaining 84 eyes, 14 (16.7%) had developed new macular atrophy at 2 years, the square root of the growth rate of atrophy was 0.52 mm/year. In multivariate analyses, a poorer best-corrected visual acuity (P = 0.01) and the presence of intraretinal fluid (P = 0.04) at baseline were found to be the independent predictors for the development of macular atrophy. No factors were found that were significantly related to the growth rate of the macular atrophy. Conclusions: Our study determined the incidence and rate of growth of macular atrophy after IVAs for neovascular AMD in clinical settings. Eyes with vision reduction and intraretinal fluid at the baseline develop macular atrophy more frequently after IVAs for neovascular AMD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration.
- Author
-
Yamamoto, akiko, Okada, annabelle a., Nakayama, Makiko, Yoshida, Yumiko, and Kobayashi, Hiroaki
- Subjects
- *
RETINAL degeneration , *MEDICAL records , *EXUDATION (Botany) , *DEGENERATION (Pathology) , *RETINAL diseases - Abstract
Purpose: The aim of this study was to investigate the 1-year outcomes of treat-and-extend aflibercept for exudative age-related macular degeneration (AMD) in Japan. Procedures: Clinical records of 67 patients (67 eyes) were reviewed. Monthly aflibercept was administered until resolution of exudation and maximal reduction of pigment epithelial detachment. Injection intervals were extended by 2-week units up to 12 weeks if no exudation was observed and shortened for recurrence. Results: Mean best-corrected visual acuity (logarithm of the minimum angle of resolution) improved from 0.29 to 0.14 at 12 months (p < 0.0001). Mean central retinal thickness decreased from 430 μm to 236 μm at 12 months (p < 0.0001). Fifty-nine eyes (88.0%) achieved a dry macula with a mean of 8.3 injections by study end. The injection interval was extended to 10 weeks in 44.8% and to 12 weeks in 17.9% of eyes. Conclusions: At 1 year, good outcomes were obtained using treat-and-extend aflibercept for exudative AMD in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
- Author
-
Yamamoto, Akiko, Okada, Annabelle A., Kano, Mariko, Koizumi, Hideki, Saito, Masaaki, Maruko, Ichiro, Sekiryu, Tetsuju, and Iida, Tomohiro
- Subjects
- *
POLYPOIDAL choroidal vasculopathy , *EYE diseases , *HEALTH outcome assessment , *VISUAL acuity , *OPTICAL coherence tomography , *RETROSPECTIVE studies , *PATIENTS , *THERAPEUTICS - Abstract
Purpose To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV). Design Retrospective, multicenter, consecutive case series. Participants A total of 90 eyes of 87 patients with treatment-naïve PCV followed at 3 tertiary centers. Methods Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening. Main Outcome Measures Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year. Results The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months ( P < 0.001). The mean central retinal thickness decreased from 315 μm at baseline to 204 μm at 12 months ( P < 0.001). At 12 months, 64 eyes (71.1%) achieved a dry macula, defined as absence of intraretinal or subretinal fluid on OCT. Of 83 eyes that underwent indocyanine green angiography at both baseline and 12 months, 46 (55.4%) showed complete and 27 (32.5%) showed partial resolution of polypoidal lesions. Eleven of 82 eyes (13.4%) showed decreased size of branching choroidal vascular networks. Conclusions Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naïve eyes with PCV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
- Author
-
Hideki Koizumi, Mariko Kano, Akiko Yamamoto, Masaaki Saito, Ichiro Maruko, Tetsuju Sekiryu, Okada, Annabelle A., and Tomohiro Iida
- Subjects
POLYPOIDAL choroidal vasculopathy ,RECOMBINANT fusion proteins ,RETINAL degeneration treatment ,CHOROID diseases ,RECOMBINANT proteins ,THERAPEUTICS - Abstract
Background/aims To investigate short-term outcomes of intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV). Methods 91 eyes of 88 consecutive patients with treatment-naive PCV examined at three university hospitals received IAI monthly for 3 months. One month after the third IAI, changes in best-corrected visual acuity (BCVA) and macular morphology were retrospectively evaluated. Additionally, possible baseline characteristics predictive of persistent retinal fluid were analysed. Results The mean BCVA (logarithm of the minimum angle of resolution units) of the 91 eyes improved from 0.31 at baseline to 0.21 at 3 months (p<0.0001). The mean central retinal thickness and mean subfoveal choroidal thickness decreased from 323 μm and 270 μm at baseline to 185 μm and 232 μm at 3 months, respectively (p<0.0001 for both). Seventy-three eyes (80.2%) achieved a dry macula defined as absence of retinal fluid. Presence of the baseline characteristics of subretinal haemorrhage and greater size of the largest polyp were significantly associated with inability to achieve a dry macula (p=0.008 and 0.03, respectively). However, this association was not found on multivariate logistic regression. Of the 90 eyes that underwent indocyanine green angiography at 3 months, 43 eyes (47.8%) showed complete and 28 eyes (31.1%) showed partial resolution of polyps. Twenty-four eyes (24.4%) also showed partial regression of branching choroidal vascular networks. Conclusions IAIs for the treatment of a large number of PCV eyes were found to improve both visual acuity and macular morphology over the short term. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients.
- Author
-
Akiko Yamamoto, Okada, Annabelle A., Atsuhiko Sugitani, Daisuke Kunita, Tosho Rii, and Reiji Yokota
- Subjects
- *
DRUG administration , *RETINAL degeneration , *DISEASES in older people , *HUMAN heredity , *VISUAL acuity - Abstract
Purpose: To describe outcomes of intravitreal ranibizumab using a pro re nata regimen for treatment-naive exudative age-related macular degeneration (AMD), in Japanese patients over the first 2 years. Methods: Clinical records were retrospectively reviewed of 48 eyes of 48 patients with treatment-naive exudative AMD who underwent intravitreal ranibizumab therapy. After three monthly injections (induction), patients were examined monthly, and subsequent injections were performed as needed (pro re nata) for any residual activity, by fundus biomicroscopy and imaging studies, regardless of severity. Results: Twenty-nine (60%) of the patients were men, and 19 (40%) were women; the mean age was 76.1 years. Of the 48 eyes evaluated, 17 (35%) had findings consistent with polypoidal choroidal vasculopathy, and five (10%) with retinal angiomatous proliferation. A mean of 6.0 ranibizumab injections were given in the first year, 3.5 in the second year, and 9.5 over the 2-year period. The best-corrected visual acuity (logarithm of minimum angle of resolution) improved significantly, from 0.35 at baseline to 0.21 at 12 months (P < 0.01), and remained stable at 0.21 at 24 months (P < 0.01). The mean central macular thickness decreased significantly, from 355.4 μm at baseline to 237.9 μm at 12 months (P < 0.01) and 247.7 μm at 24 months (P < 0.01). Conclusion: Improved visual acuity and decreased central macular thickness were observed and maintained over a 2-year period, in a Japanese population receiving 3 monthly induction injections followed by a pro re nata regimen of ranibizumab for exudative AMD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.